L
Langdon L. Miller
Researcher at National Institutes of Health
Publications - 29
Citations - 5169
Langdon L. Miller is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Idelalisib & Chronic lymphocytic leukemia. The author has an hindex of 19, co-authored 29 publications receiving 4746 citations.
Papers
More filters
Journal ArticleDOI
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
TL;DR: The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Journal ArticleDOI
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
TL;DR: In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
Journal ArticleDOI
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Jennifer R. Brown,John C. Byrd,Steven Coutre,Don M. Benson,Ian W. Flinn,Nina D. Wagner-Johnston,Stephen E. Spurgeon,Brad S. Kahl,Celeste M. Bello,Heather K. Webb,Dave Johnson,Sissy Peterman,Daniel Li,Thomas Jahn,Brian J. Lannutti,Roger G. Ulrich,Albert S. Yu,Langdon L. Miller,Richard R. Furman +18 more
TL;DR: The clinical utility of inhibiting the PI3Kδ pathway with idelalisib is demonstrated and the findings support the further development of idELalisib in patients with CLL.
Journal ArticleDOI
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
Julia Hoellenriegel,Sarah A. Meadows,Mariela Sivina,William G. Wierda,Hagop M. Kantarjian,Michael J. Keating,Neill A. Giese,Susan O'Brien,Albert S. Yu,Langdon L. Miller,Brian J. Lannutti,Jan A. Burger +11 more
TL;DR: CAL-101 displays a dual mechanism of action, directly decreasing cell survival while reducing interactions that retain CLL cells in protective tissue microenvironments, and a roadmap for future therapeutic development.
Journal ArticleDOI
A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
Susan O'Brien,Nicole Lamanna,Thomas J. Kipps,Ian W. Flinn,Andrew D. Zelenetz,Jan A. Burger,Michael J. Keating,Siddhartha Mitra,Leanne Holes,Albert S. Yu,David W. Johnson,Langdon L. Miller,Yeonhee Kim,Roger Dansey,Ronald L. Dubowy,Steven Coutre +15 more
TL;DR: The combination of idelalisib and rituximab was highly active, resulting in durable disease control in treatment-naïve older patients with CLL, and support the further development of idELalisib as initial treatment of CLL.